XML 22 R11.htm IDEA: XBRL DOCUMENT
v3.25.3

Revenues | 9 Months Ended
--- | ---
Sep. 30, 2025
Revenue from Contract with Customer [Abstract] |
Revenues | Revenues We operate our business in one operating segment, which also represents one reportable segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. A substantial portion of ROW product sales relates to products sold in Europe. Revenues were as follows (in millions):
|  | Three months ended September 30,
|  | 2025 |  | 2024
|  | U.S. |  | ROW |  | Total |  | U.S. |  | ROW |  | Total
Prolia |  | $ | 806 |  |  | $ | 333 |  |  | $ | 1,139 |  |  | $ | 683 |  |  | $ | 362 |  |  | $ | 1,045 |
Repatha |  | 442 |  |  | 352 |  |  | 794 |  |  | 281 |  |  | 286 |  |  | 567 |
ENBREL |  | 574 |  |  | 6 |  |  | 580 |  |  | 817 |  |  | 8 |  |  | 825 |
Otezla |  | 473 |  |  | 112 |  |  | 585 |  |  | 460 |  |  | 104 |  |  | 564 |
XGEVA |  | 357 |  |  | 182 |  |  | 539 |  |  | 373 |  |  | 168 |  |  | 541 |
EVENITY |  | 417 |  |  | 124 |  |  | 541 |  |  | 289 |  |  | 110 |  |  | 399 |
TEPEZZA |  | 518 |  |  | 42 |  |  | 560 |  |  | 482 |  |  | 6 |  |  | 488 |
BLINCYTO |  | 236 |  |  | 156 |  |  | 392 |  |  | 237 |  |  | 90 |  |  | 327 |
Nplate |  | 333 |  |  | 124 |  |  | 457 |  |  | 345 |  |  | 111 |  |  | 456 |
KYPROLIS |  | 225 |  |  | 134 |  |  | 359 |  |  | 238 |  |  | 140 |  |  | 378 |
Aranesp |  | 103 |  |  | 254 |  |  | 357 |  |  | 105 |  |  | 232 |  |  | 337 |
TEZSPIRE(1) |  | 377 |  |  | — |  |  | 377 |  |  | 269 |  |  | — |  |  | 269 |
KRYSTEXXA |  | 320 |  |  | — |  |  | 320 |  |  | 310 |  |  | — |  |  | 310 |
Vectibix |  | 162 |  |  | 122 |  |  | 284 |  |  | 132 |  |  | 150 |  |  | 282 |
Other products(2) |  | 1,408 |  |  | 445 |  |  | 1,853 |  |  | 958 |  |  | 405 |  |  | 1,363 |
Total product sales(3) |  | $ | 6,751 |  |  | $ | 2,386 |  |  | 9,137 |  |  | $ | 5,979 |  |  | $ | 2,172 |  |  | 8,151 |
Other revenues |  |  |  |  |  | 420 |  |  |  |  |  |  | 352 |
Total revenues |  |  |  |  |  | $ | 9,557 |  |  |  |  |  |  | $ | 8,503 |
|  | Nine months ended September 30,
|  | 2025 |  | 2024
|  | U.S. |  | ROW |  | Total |  | U.S. |  | ROW |  | Total
Prolia |  | $ | 2,271 |  |  | $ | 1,089 |  |  | $ | 3,360 |  |  | $ | 2,110 |  |  | $ | 1,099 |  |  | $ | 3,209 |
Repatha |  | 1,146 |  | 1,000 |  | 2,146 |  |  | 824 |  | 792 |  | 1,616 |
ENBREL |  | 1,675 |  | 19 |  | 1,694 |  |  | 2,280 |  | 21 |  | 2,301 |
Otezla |  | 1,328 |  | 312 |  | 1,640 |  |  | 1,185 |  | 317 |  | 1,502 |
XGEVA |  | 1,064 |  | 573 |  | 1,637 |  |  | 1,138 |  | 526 |  | 1,664 |
EVENITY |  | 1,132 |  | 369 |  | 1,501 |  |  | 806 |  | 326 |  | 1,132 |
TEPEZZA |  | 1,349 |  | 97 |  | 1,446 |  |  | 1,379 |  |  | 12 |  |  | 1,391 |
BLINCYTO |  | 779 |  | 367 |  | 1,146 |  |  | 555 |  | 280 |  | 835 |
Nplate |  | 762 |  | 377 |  | 1,139 |  |  | 749 |  | 370 |  | 1,119 |
KYPROLIS |  | 673 |  | 388 |  | 1,061 |  |  | 712 |  | 419 |  | 1,131 |
Aranesp |  | 301 |  | 755 |  | 1,056 |  |  | 296 |  | 738 |  | 1,034 |
TEZSPIRE(1) |  | 1,004 |  | — |  |  | 1,004 |  |  | 676 |  | — |  |  | 676 |
KRYSTEXXA |  | 905 |  | — |  |  | 905 |  |  | 839 |  |  | — |  |  | 839 |
Vectibix |  | 441 |  | 415 |  | 856 |  |  | 385 |  | 414 |  | 799 |
Other products(2) |  | 3,907 |  |  | 1,283 |  | 5,190 |  |  | 2,858 |  |  | 1,204 |  | 4,062 |
Total product sales(3) |  | $ | 18,737 |  |  | $ | 7,044 |  |  | 25,781 |  |  | $ | 16,792 |  |  | $ | 6,518 |  |  | 23,310 |
Other revenues |  |  |  |  |  | 1,104 |  |  |  |  |  |  | 1,028 |
Total revenues |  |  |  |  |  | $ | 26,885 |  |  |  |  |  |  | $ | 24,338 |
_______ (1) TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States. (2) Consists of product sales of our non-principal products. (3) Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2025 and 2024.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration